Targeting tumor endothelial hyperglycolysis enhances immunotherapy through remodeling tumor microenvironment

Fridman, 2020, Therapeutic targeting of the colorectal tumor stroma, Gastroenterology, 158, 303, 10.1053/j.gastro.2019.09.045 Shaked, 2019, The pro-tumorigenic host response to cancer therapies, Nat Rev Cancer, 19, 667, 10.1038/s41568-019-0209-6 De Palma, 2017, Microenvironmental regulation of tumour angiogenesis, Nat Rev Cancer, 17, 457, 10.1038/nrc.2017.51 Apte, 2019, VEGF in signaling and disease: beyond discovery and development, Cell, 176, 1248, 10.1016/j.cell.2019.01.021 Chaudhary, 2012, TEM8/ANTXR1 blockade inhibits pathological angiogenesis and potentiates tumoricidal responses against multiple cancer types, Cancer Cell, 21, 212, 10.1016/j.ccr.2012.01.004 Yi, 2019, Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment, Mol Cancer, 18, 60, 10.1186/s12943-019-0974-6 Cheng, 2020, Remodeling the homeostasis of pro- and anti-angiogenic factors by Shenmai injection to normalize tumor vasculature for enhanced cancer chemotherapy, J Ethnopharmacol, 270, 113770, 10.1016/j.jep.2020.113770 Zhong, 2020, Identification of bioactive anti-angiogenic components targeting tumor endothelial cells in Shenmai injection using multidimensional pharmacokinetics, Acta Pharm Sin B, 10, 1694, 10.1016/j.apsb.2019.12.011 Allen, 2017, Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation, Sci Transl Med, 9, 10.1126/scitranslmed.aak9679 Huang, 2018, Improving immune–vascular crosstalk for cancer immunotherapy, Nat Rev Immunol, 18, 195, 10.1038/nri.2017.145 Meder, 2018, Combined VEGF and PD-L1 blockade displays synergistic treatment effects in an autochthonous mouse model of small cell lung cancer, Cancer Res, 78, 4270, 10.1158/0008-5472.CAN-17-2176 Hegde, 2020, Top 10 challenges in cancer immunotherapy, Immunity, 52, 17, 10.1016/j.immuni.2019.12.011 Zhang, 2020, Endothelial lactate controls muscle regeneration from ischemia by inducing M2-like macrophage polarization, Cell Metabol, 31, 1136, 10.1016/j.cmet.2020.05.004 Yang, 2018, PRKAA1/AMPKα1-driven glycolysis in endothelial cells exposed to disturbed flow protects against atherosclerosis, Nat Commun, 9, 4667, 10.1038/s41467-018-07132-x Potente, 2017, The link between angiogenesis and endothelial metabolism, Annu Rev Physiol, 79, 43, 10.1146/annurev-physiol-021115-105134 Fitzgerald, 2018, The warburg effect in endothelial cells and its potential as an anti-angiogenic target in cancer, Front Cell Dev Biol, 6, 100, 10.3389/fcell.2018.00100 Eelen, 2018, Endothelial cell metabolism, Physiol Rev, 98, 3, 10.1152/physrev.00001.2017 Jakobsson, 2010, Endothelial cells dynamically compete for the tip cell position during angiogenic sprouting, Nat Cell Biol, 12, 943, 10.1038/ncb2103 Falkenberg, 2019, The metabolic engine of endothelial cells, Nat Metab, 1, 937, 10.1038/s42255-019-0117-9 Wu, 2017, HIF-1α is required for disturbed flow-induced metabolic reprogramming in human and porcine vascular endothelium, Elife, 6, 10.7554/eLife.25217 Feng, 2017, Mechanical activation of hypoxia-inducible factor 1α drives endothelial dysfunction at atheroprone sites, Arterioscler Thromb Vasc Biol, 37, 2087, 10.1161/ATVBAHA.117.309249 Shevchenko, 2006, In-gel digestion for mass spectrometric characterization of proteins and proteomes, Nat Protoc, 1, 2856, 10.1038/nprot.2006.468 Chi, 2018, Comprehensive identification of peptides in tandem mass spectra using an efficient open search engine, Nat Biotechnol, 36, 1059, 10.1038/nbt.4236 Chang, 2013, Posttranscriptional control of T cell effector function by aerobic glycolysis, Cell, 153, 1239, 10.1016/j.cell.2013.05.016 Kornberg, 2018, Dimethyl fumarate targets GAPDH and aerobic glycolysis to modulate immunity, Science, 360, 449, 10.1126/science.aan4665 Lomenick, 2009, Target identification using drug affinity responsive target stability (DARTS), Proc Natl Acad Sci U S A, 106, 21984, 10.1073/pnas.0910040106 Nagasaka, 2021, Beyond osimertinib: the development of 3rd-generation EGFR tyrosine kinase inhibitors, J Thorac Oncol, 16, 5740, 10.1016/j.jtho.2020.11.028 Ballard, 2016, Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases Activity, Clin Cancer Res, 22, 5130, 10.1158/1078-0432.CCR-16-0399 Fukumura, 2018, Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges, Nat Rev Clin Oncol, 15, 325, 10.1038/nrclinonc.2018.29 Pavlova, 2016, The emerging hallmarks of cancer metabolism, Cell Metabol, 23, 27, 10.1016/j.cmet.2015.12.006 Galon, 2020, Tumor immunology and tumor evolution: intertwined histories, Immunity, 52, 55, 10.1016/j.immuni.2019.12.018 Kerbel, 2008, Tumor angiogenesis, N Engl J Med, 358, 2039, 10.1056/NEJMra0706596 De Bock, 2013, Role of PFKFB3-driven glycolysis in vessel sprouting, Cell, 154, 651, 10.1016/j.cell.2013.06.037 Yu, 2017, FGF-dependent metabolic control of vascular development, Nature, 545, 224, 10.1038/nature22322 Carmeliet, 2011, Molecular mechanisms and clinical applications of angiogenesis, Nature, 473, 298, 10.1038/nature10144 Cantelmo, 2016, Inhibition of the glycolytic activator PFKFB3 in endothelium induces tumor vessel normalization, impairs metastasis, and improves chemotherapy, Cancer Cell, 30, 968, 10.1016/j.ccell.2016.10.006 Shestov, 2014, Quantitative determinants of aerobic glycolysis identify flux through the enzyme GAPDH as a limiting step, Elife, 3, 10.7554/eLife.03342 Samson, 2014, Oxidation of an exposed methionine instigates the aggregation of glyceraldehyde-3-phosphate dehydrogenase, J Biol Chem, 289, 26922, 10.1074/jbc.M114.570275 Roskoski, 2021, Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs), Pharmacol Res, 165, 105422, 10.1016/j.phrs.2021.105422 Vasan, 2019, A view on drug resistance in cancer, Nature, 575, 299, 10.1038/s41586-019-1730-1 Finlay, 2014, Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor, J Med Chem, 57, 8249, 10.1021/jm500973a Yver, 2016, Osimertinib (AZD9291)-a science-driven, collaborative approach to rapid drug design and development, Ann Oncol, 27, 1165, 10.1093/annonc/mdw129 Hochmair, 2018, Medical treatment options for patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer suffering from brain metastases and/or leptomeningeal disease, Targeted Oncol, 13, 269, 10.1007/s11523-018-0566-1 Mok, 2017, Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer, N Engl J Med, 376, 629, 10.1056/NEJMoa1612674 Zhu, 2019, Receptor tyrosine kinase fusions as an actionable resistance mechanism to EGFR TKIs in EGFR-mutant non-small-cell lung cancer, Trends Cancer, 5, 677, 10.1016/j.trecan.2019.09.008 Stone, 2018, Loss of pyruvate kinase M2 limits growth and triggers innate immune signaling in endothelial cells, Nat Commun, 9, 4077, 10.1038/s41467-018-06406-8 Wu, 2021, Intercellular transfer of exosomal wild type EGFR triggers osimertinib resistance in non-small cell lung cancer, Mol Cancer, 20, 17, 10.1186/s12943-021-01307-9 Yu, 2020, Phase I study of the efficacy and safety of ramucirumab in combination with osimertinib in advanced T790M-positive EGFR-mutant non-small cell lung cancer, Clin Cancer Res, 27, 992, 10.1158/1078-0432.CCR-20-1690 Akamatsu, 2021, JAMA Oncol, 7, 386, 10.1001/jamaoncol.2020.6758 Schmittnaegel, 2017, Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade, Sci Transl Med, 9, 10.1126/scitranslmed.aak9670 Park, 2016, Normalization of tumor vessels by Tie2 activation and Ang2 inhibition enhances drug delivery and produces a favorable tumor microenvironment, Cancer Cell, 30, 953, 10.1016/j.ccell.2016.10.018 Angelin, 2017, Foxp3 reprograms T cell metabolism to function in low-glucose, high-lactate environments, Cell Metabol, 25, 1282, 10.1016/j.cmet.2016.12.018 Liu, 2019, Lactate inhibits ATP6V0d2 expression in tumor-associated macrophages to promote HIF-2α-mediated tumor progression, J Clin Invest, 129, 631, 10.1172/JCI123027 García-Cañaveras, 2019, The tumor metabolic microenvironment: lessons from lactate, Cancer Res, 79, 3155, 10.1158/0008-5472.CAN-18-3726 Peng, 2012, PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines, Cancer Res, 72, 5209, 10.1158/0008-5472.CAN-12-1187 Oxnard, 2020, TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer, Ann Oncol, 31, 507, 10.1016/j.annonc.2020.01.013 Lin, 2019, Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations, Mol Cancer, 18, 139, 10.1186/s12943-019-1062-7